The content on this site is intended for healthcare professionals only
Dr Mahon presents data at ASH 2016 with an update from the EURO-SKI trial of TKI cessation for myeloid leukaemia patients.
This update follows results presented at EHA 2016, which ecancer covered here.
Coverage of the press conference in which new data was presented is available here, and more detail is available through ecancer news here.
Dose reduction of TKI therapy was also discussed by Prof Mhairi Copeland, here, and these findings were discussed by Dr Mikkael Sekeres here.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 4th - 10th, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
